Texas Medical Center Venture Fund

Texas Medical Center Venture Fund invests from Houston with $1M to $5M checks at seed through Series B, drawing on the Texas Medical Center’s position as the largest medical complex in the world. The fund’s defining feature is access: portfolio companies can run pilots, recruit clinical advisors, and validate products inside an ecosystem of dozens of hospitals, research institutions, and specialty centers operating in close physical and operational proximity. For founders building healthcare technology, that access is often the decisive consideration.

The thesis covers digital health, medical devices and medtech, and biotech. The fund backs companies whose products can plausibly find clinical or commercial traction within the TMC ecosystem, including software that improves clinical workflows, devices that need rigorous clinical validation, and biotech companies that benefit from access to academic medical research. The fund is open to companies headquartered outside Texas, provided they are willing to engage substantively with TMC institutions for pilots, validation, or commercial partnerships, and it will often facilitate those connections during diligence.

Check sizes of $1M to $5M place TMC Venture Fund as a participating investor in seed and Series A rounds, with selective Series B activity. The geographic mandate is broad, but the practical center of gravity is companies that engage with TMC. Founders should expect a diligence process that includes input from clinical and research leaders within TMC institutions, and they should treat the relationship as both a financial and a commercial one. The fund’s connection to TMC is its most differentiated asset and is reflected in how it evaluates and supports companies.

The team includes investors with backgrounds across venture, operating, and clinical research, working closely with the broader TMC innovation infrastructure, including TMC Innovation, the accelerator program that connects startups to TMC member institutions. That structure gives portfolio companies a path into the ecosystem that would be difficult to build independently, particularly for early-stage companies that lack the relationships to navigate large academic medical centers.

TMC Venture Fund’s working style is collaborative and ecosystem-driven. The fund typically takes board observer roles and engages on commercial strategy, particularly around clinical pilots, regulatory pathways, and partnerships with TMC member institutions. It co-invests alongside traditional venture firms and other healthcare-focused investors, and it supports portfolio companies through subsequent rounds and commercial expansion. Founders building digital health, medtech, or biotech products that benefit from validation and commercial traction inside a major academic medical complex, and who want an investor whose structural advantage is access rather than capital alone, will find TMC Venture Fund well-positioned. Founders without a meaningful commercial story tied to academic medical centers will find less leverage in the relationship.